(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 March 2005 (17.03.2005)

PCT

(10) International Publication Number
WO 2005/023806 A2

(51) International Patent Classification[7]: C07D 471/00

(21) International Application Number:
PCT/US2004/028899

(22) International Filing Date:
3 September 2004 (03.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/500,414 5 September 2003 (05.09.2003) US

(71) Applicants *(for all designated States except US)*: **NEUROGEN CORPORATION** [US/US]; 35 N.E. Industrial Road, Branford, CT 06405 (US). **AVENTIS PHARMACEUTICALS INC.** [US/US]; 300 Summerset Corporate Boulevard, Bridgewater, NJ 08807-2854 (US).

(72) Inventors: **GE, Ping**; 718R Higganum Road, Durham, CT 06422 (US). **HORVATH, Raymond, F.**; 973 Little Meadow, Guilford, CT 06437 (US). **ZHANG, Lu, Yan**; 83 Florence Road, Apt. 2C, Branford, CT 06405 (US). **YAMAGUCHI, Yasuchika**; 516 Lake Drive, Guilford, CT 06437 (US). **KAISER, Bernd**; 93 Hintz Drive, Wallingford, CT 06492 (US). **ZHANG, Xuechun**; 4 Brushy Plains Road, #221, Branford, CT 06405 (US). **ZHANG, Suoming**; 71 Florence Road, #2A, Branford, CT 06405 (US). **ZHAO, He**; 4 Stoneridge Lane, Brandford, CT 06405 (US). **JOHN, Stanly**; 77 Vanderveer Drive, Basking Ridge, NJ 07920 (US). **MOORCROFT, Neil**; 603 Route 173, Bloomsbury, NJ 08804 (US). **SHUTSKE, Greg**; 3 Dark Hollow Road, Pittstown, NJ 08867 (US).

(74) Agents: **ALEXANDER, John, B., Ph.D.** et al.; Edwards & Angell, LLP, P.O. Box 55874, Boston, MA 02205 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv)) for US only*

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HETEROARYL FUSED PYRIDINES, PYRAZINES AND PYRIMIDINES AS CRF1 RECEPTOR LIGANDS

(57) Abstract: Substituted heteroaryl fused pyridine, pyrazine, and pyrimidine compounds that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and peripheral disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

WO 2005/023806 A2